Literature DB >> 15843128

Reversal of left ventricular hypertrophy by propranolol in hypertensive rats.

Charles I Maina1, Maurice Ogunde.   

Abstract

BACKGROUND: Hypertension contributes significantly to the development of left ventricular hypertrophy. Left ventricular hypertrophy is associated with increased incidence of sudden cardiac death. Recognition and management of hypertension is, therefore, imperative.
OBJECTIVE: To establish whether propranolol can reverse left ventricular hypertrophy in hypertensive rats.
METHODS: Hypertension was induced in male albino rats by giving them 1% NaCl solution as their only drink for four weeks. Propranolol was then administered orally to one of the four groups of rats used in this study. Systolic blood pressure of each rat was measured twice a week using a modified tail-cuff method. Each rat was then sacrificed, its heart excised from the chest cavity and geometric studies carried on the left ventricle.
RESULTS: Excessive intake of sodium salt by the rats caused an increase in their systolic blood pressure which was accompanied by left ventricular hypertrophy. The elevated blood pressure (139.4 +/- 0.5 mm Hg) was, however, brought back to normal (108.4 +/- 0.2 mm Hg) by propranolol. Data on weight, thickness, and volume of the left ventricle strongly indicated that propranolol can reverse ventricular hypertrophy.
CONCLUSION: Propranolol reverses left ventricular hypertrophy besides lowering elevated systolic blood pressure in rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843128      PMCID: PMC1831908     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  14 in total

1.  The fourth Volhard lecture: cardiovascular structural adaptation; its role in the initiation and maintenance of primary hypertension.

Authors:  B Folkow
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

2.  Salt sensitivity, pulse pressure, and death in normal and hypertensive humans.

Authors:  M H Weinberger; N S Fineberg; S E Fineberg; M Weinberger
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

3.  Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats.

Authors:  J M Pfeffer; M A Pfeffer; E D Frohlich
Journal:  J Lab Clin Med       Date:  1971-12

4.  Cardiac responses to increased afterload. State-of-the-art review.

Authors:  R C Tarazi; M N Levy
Journal:  Hypertension       Date:  1982 May-Jun       Impact factor: 10.190

Review 5.  Hypertension, left ventricular hypertrophy, and sudden death.

Authors:  Lwin Lwin Tin; D Gareth Beevers; Gregory Y H Lip
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

6.  USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

Authors:  B N PRICHARD; P M GILLAM
Journal:  Br Med J       Date:  1964-09-19

7.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 8.  Historic and early life origins of hypertension in Africans.

Authors:  Terrence Forrester
Journal:  J Nutr       Date:  2004-01       Impact factor: 4.798

9.  Quantitative analysis of cardiac hypertrophy due to pressure load in reference to the relations of blood pressure, left ventricular weight and left ventricular capacity.

Authors:  S Arai; T Nakamura; N Suwa
Journal:  Tohoku J Exp Med       Date:  1976-04       Impact factor: 1.848

10.  Does whole body autoregulation mediate the hemodynamic responses to increased dietary salt in rats with clamped ANG II?

Authors:  Deborah M Fine; Pilar Ariza-Nieto; John W Osborn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-08-07       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.